[1]王尚全*,冯泳铿*,陈明△,等.不同肾虚证型的绝经后骨质疏松骨代谢标志物相关性研究[J].中国中医骨伤科杂志,2024,32(07):29-33.[doi:10.20085/j.cnki.issn1005-0205.240705 ]
　WANG Shangquan*,FENG Yongkeng*,CHEN Ming,et al.Study on the Correlation of Bone Metabolic Markers in Different Kidney Deficiency Syndrome Types of Postmenopausal Osteoporosis[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2024,32(07):29-33.[doi:10.20085/j.cnki.issn1005-0205.240705 ]
点击复制

不同肾虚证型的绝经后骨质疏松骨代谢标志物相关性研究()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第32卷
期数:
2024年07期
页码:
29-33
栏目:
临床研究
出版日期:
2024-07-15

文章信息/Info

Title:
Study on the Correlation of Bone Metabolic Markers in Different Kidney Deficiency Syndrome Types of Postmenopausal Osteoporosis
文章编号:
1005-0205(2024)07-0029-05
作者:
王尚全1; 2*; 冯泳铿1*; 陈明1; 2△; 李玲慧1; 田婧1; 尹煜辉1; 王达1; 艾晨晨1; 蔡明扬1
1中国中医科学院望京医院(北京,100102)
2中医正骨技术北京市重点实验室
Author(s):
WANG Shangquan1; 2*; FENG Yongkeng1*; CHEN Ming1; 2△; LI Linghui1; TIAN Jing1; YIN Yuhui1; WANG Da1; AI Chenchen1; CAI Mingyang1
1Wangjing Hospital of Chinese Academy of Traditional Chinese Medicine,Beijing 100102,China; 2Beijing Key Laboratory of Chinese Bone-Setting Technology,Beijing 100102,China.
关键词:
绝经后骨质疏松症;  肝肾阴虚;  肾阳虚;  中医证型
Keywords:
postmenopausal osteoporosis;  liver-kidney Yin deficiency;  kidney Yang deficiency;  syndrome
分类号:
R68
DOI:
10.20085/j.cnki.issn1005-0205.240705
文献标志码:
A
摘要:
目的:通过对不同肾虚证型绝经后骨质疏松症患者的血清指标进行分析,探索不同证型之间的血清学差异,为绝经后骨质疏松症患者的中医证型分析提供客观依据。方法:选取2021年2月至2022年1月,年龄为45～80岁,符合肝肾阴虚及肾阳虚两个证型的绝经后骨质疏松症患者,记录其骨密度、一般临床特征及骨代谢标志物,比较不同证型的各指标之间的差异。结果:肾阳虚证组53例,肝肾阴虚证组40例。经年龄与体重指数一比一配对统计学分析,发现肾阳虚证组患者β-CTX水平明显高于肝肾阴虚证组(P<0.05),肝肾阴虚证组患者血清甲状旁腺激素(PTH)水平明显高于肾阳虚证组(P<0.05),差异均有统计学意义。结论:绝经后骨质疏松症中,肾阳虚患者的骨吸收程度可能更高,而肝肾阴虚患者更具有甲状旁腺病理学改变的倾向性。
Abstract:
Objective:To explore the serological differences between different types of evidence and provide an objective basis for the analysis of Chinese medicine evidence in postmenopausal osteoporosis patients by analyzing the serum indexes of postmenopausal osteoporosis patients with different kidney deficiency types.Methods:45 80 years old osteoporosis patients with menopause were selected from February 2021 to January 2022 with two syndrome types of liver-kidney Yin deficiency and kidney Yang deficiency.Bone mineral density(BMD),general clinical features and bone metabolism markers were collected,and the differences of indicators among different syndrome types were compared.Results:Among the 93 patients,53 were in the kidney Yang deficiency syndrome group and 40 were in the liver-kidney Yin deficiency syndrome group.It was found that the β-CTX level of patients with kidney Yang deficiency was significantly higher than that of the liver-kidney Yin deficiency group after statistical analysis of one-to-one matching of age and body mass index(BMI)(P<0.05),and the serum parathyroid hormone(PTH)level of patients of the liver-kidney Yin deficiency group was significantly higher than that of the kidney Yang deficiency group(P<0.05),both differences were statistically significant.Conclusion:In postmenopausal osteoporosis,the level of bone resorption may be higher in patients with kidney Yang deficiency,whereas patients with live-kidney Yin deficiency are more predisposed to altered parathyroid pathology.

参考文献/References:

[1] CUI H,LI J,LI X,et al.TNF-α promotes osteocyte necroptosis by upregulating TLR4 in postmenopausal osteoporosis[J].Bone,2024:117050.
[2] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中国骨质疏松杂志,2019,25(3):281-309.
[3] 中华中医药学会.绝经后骨质疏松症(骨痿)中医药诊疗指南(2019年版)[J].中医正骨,2020,32(2):1-13.
[4] 中国老年学和老年医学学会骨质疏松分会中医药专家委员会.中医药防治原发性骨质疏松症专家共识(2020)[J].中国骨质疏松杂志,2020,26(12):1717-1725.
[5] REN Z,WANG Y,AO G,et al.Overall adjustment acupuncture for postmenopausal osteoporosis(PMOP):a study protocol for a randomized sham-controlled trial[J].Trials,2020,21(1):465.
[6] CHENG C H,CHEN L R,CHEN K H.Osteoporosis due to hormone imbalance:an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover[J].Int J Mol Sci,2022,23(3):1376.
[7] 麻永胜,蒋宜伟,宋重东,等.从“滋水涵木”论治肝肾阴虚型绝经后骨质疏松症[J].现代中西医结合杂志,2023,32(7):983-986.
[8] 张宝荣,谭颖颖.左归丸加味对绝经后骨质疏松妇女血清E2、IL-6和IGF-1水平的影响[J].陕西中医学院学报,2015,38(4):55-57.
[9] 江南,李春梅,张艺,等.肝肾同补治疗绝经后骨质疏松症的临床研究[J].中医药信息,2017,34(5):52-54.
[10] BROWN J P,DON-WAUCHOPE A,DOUVILLE P,et al.Current use of bone turnover markers in the management of osteoporosis[J].Clin Biochem,2022,109/110:1-10.
[11] SHIEH A,ISHII S,GREENDALE G,et al.Urinary n-telopeptide and rate of bone loss over the menopause transition and early postmenopause[J].Journal of Bone and Mineral Research:The Official Journal of the American Society for Bone and Mineral Research,2016,31(11):2057-2064.
[12] KELLY J.Bone turnover markers in osteoporosis[J].JAMA,2019,322(23):2344.
[13] WEN H,HUANG T,LI T,et al.Effects of short-term step aerobics exercise on bone metabolism and functional fitness in postmenopausal women with low bone mass[J].Randomized Controlled Trial,2017,28(2):539-547.
[14] SEELY K D,KOTELKO C A,DOUGLAS H,et al.The human gut microbiota:a key mediator of osteoporosis and osteogenesis[J].Int J Mol Sci,2021,22(17):9452.
[15] CHEN X,XU J,ZHANG H,et al.A nomogram for predicting osteoarthritis based on serum biomarkers of bone turnover in middle age:a cross-sectional study of PTH and β-CTX[J].Medicine,2023,102(20):e33833.
[16] HU Q,WANG Q,LIU F,et al.Combination of calcitriol and zoledronic acid on PINP and β-CTX in postoperative patients with diabetic osteoporosis:a randomized controlled trial[J].Dis Markers,2022:6053410.
[17] EASTELL R,SZULC P.Use of bone turnover markers in postmenopausal osteoporosis[J].The Lancet Diabetes & Endocrinology,2017,5(11):908-923.
[18] JIANG X,YAN N,ZHENG Y,et al.Risk of primary osteoporosis score(RPOPs):an algorithm model for primary osteoporosis risk assessment in grass-roots hospital[J].BMC Musculoskelet Disord,2022,23(1):1041.
[19] 张鹏,罗伟,张冬梅,等.老年骨质疏松症不同中医证型中BMD、25(OH)D3及PTH的比较和相关性分析[J].四川中医,2020,38(4):81-83.
[20] SILVA B C,BILEZIKIAN J P.Skeletal abnormalities in hypoparathyroidism and in primary hyperparathyroidism[J].Rev Endocr Metab Disord,2021,22(4):789-802.
[21] EJLSMARK-SVENSSON H,ROLIGHED L,HARSLØF T,et al.Risk of fractures in primary hyperparathyroidism:a systematic review and meta-analysis[J].Osteoporos Int,2021,32(6):1053-1060.
[22] KUMA M,JACKULIAK P,KILLINGER Z,et al.Parathyroid hormone-related changes of bone structure[J].Physiol Res,2021,70(Suppl 1):S3-S11.
[23] 罗颂平,张玉珍.罗元恺女科述要[M].广州:广东高等教育出版社,1993.
[24] 陈灏珠.实用内科学:上册[M].北京; 人民卫生出版社,2006:1265-1270.
[25] BILEZIKIAN J P,BANDEIRA L,KHAN A,et al.Hyperparathyroidism[J].Lancet,2018,391(10116):168-178.
[26] SILVA B C,CUSANO N E,BILEZIKIAN J P.Primary hyperparathyroidism[J].Best Practice & Research Clinical Endocrinology & Metabolism,2018,32(5):593-607.
[27] 张雅冬,许昕.许昕教授运用“治肝六法”治疗妇科疾病探赜[J].河北中医,2022,44(8):1249-1253.

备注/Memo

备注/Memo:
基金项目:中国中医科学院望京医院院级科研课题(WJYY2020-24)
中国中医科学院望京医院自主选题专项课题(WJYY-ZZXT-2022-01)
中国中医科学院科技创新工程团队课题(CI2021B010-03)
△通信作者 E-mail:1520973174@qq.com
*共同第一作者
更新日期/Last Update: 2024-07-05